ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ARWR Arrowhead Pharmaceuticals Inc

23.17
0.55 (2.43%)
01 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Arrowhead Pharmaceuticals Inc NASDAQ:ARWR NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.55 2.43% 23.17 22.87 23.85 23.84 22.62 22.72 1,113,561 22:30:00

Robbins Arroyo LLP Is Investigating the Officers and Directors of Arrowhead Research Corporation (ARWR) on Behalf of Sharehol...

14/01/2015 7:58pm

PR Newswire (US)


Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Arrowhead Pharmaceuticals Charts.

SAN DIEGO and PASADENA, Calif., Jan. 14, 2015 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Arrowhead Research Corporation (NASDAQGS: ARWR) breached their fiduciary duties to shareholders. Arrowhead is a biopharmaceutical company that develops targeted RNAi therapeutics in the United States.

Robbins Arroyo LLP.

View this press release on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/arrowhead-research-corporation

Arrowhead to Cut Hepatitis B Drug Study Dosage in Mid-Stage Trial  

On January 12, 2015, Arrowhead stock fell over 23% to close at $6.90 per share after the company announced that the U.S. Food and Drug Administration verbally informed the company of a partial clinical hold on its ARC-520 study for patients with chronic hepatitis B. The FDA has informed Arrowhead that it will need to start a new, multi-dose study at one mg/kg instead of the proposed two and four mg/kg. In addition, the FDA has requested additional information from the drug's current mid-stage study.          

Arrowhead Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, DDonahue@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. 

Attorney Advertising. Past results do not guarantee a similar outcome.  

Contact:
Darnell R. Donahue
Robbins Arroyo LLP
600 B Street, Suite 1900
San Diego, Ca 92101
DDonahue@robbinsarroyo.com 
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36754LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/robbins-arroyo-llp-is-investigating-the-officers-and-directors-of-arrowhead-research-corporation-arwr-on-behalf-of-shareholders-300020753.html

SOURCE Robbins Arroyo LLP

Copyright 2015 PR Newswire

1 Year Arrowhead Pharmaceuticals Chart

1 Year Arrowhead Pharmaceuticals Chart

1 Month Arrowhead Pharmaceuticals Chart

1 Month Arrowhead Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock